Enzyme Communications Acquired by Bioscript Group

Bioscript Group explained that its acquisition of Enzyme Communications will enhance “medical writing, scientific content creation and storytelling capabilities”.

Enzyme, managed by co-founders Neil Kumar and Adam Goodband, will go on operating under the same brand name.

According to the release, the firm will contribute “expertise in building scientific stories from data, and helping clients effectively articulate how their products change lives” to Bioscript’s medical and scientific communications section.

Gabrielle Silver, chief executive of Bioscript Group stated that ‘’The synergies between our two organisations are clear. Enzyme’s distinctive approach to strategic planning and scientific storytelling bolsters the group’s capabilities and will help our clients think even more creatively about how to define their scientific proposition across target audiences.”

Kumar asserted: “Joining Bioscript Group not only allows us to scale and enhance the services we currently offer to our clients, it also brings new opportunities for growth and development for our talented team. We can’t wait to see them thrive and progress in this partnership.”

Goodband explained: “We are a team of people who get excited about working on cutting-edge science and repackaging it in ways that are strategically relevant, creative and new. In Bioscript Group, we recognise those shared passions and compliment each other’s skill set, which will enhance our offerings to existing clients on both sides.’’